Table 1.
Demographic and Clinicopathologic Characteristics of Metaplastic and non-Metaplastic Breast Cancer Patients, National Cancer Data Base, 2010–2014
| All Patients (N=570,508) | Metaplastic (N=2,451) | Non-Metaplastic (N=568,057) | P-Value | |
|---|---|---|---|---|
| Age – Median, years (IQR) | 61 (51 – 70) | 62 (52 – 72) | 61 (51 – 70) | <0.001 |
| Follow-up–Median, months (95% CI) | 37.3 (37.3–37.4) | 37.0 (36.3–38.0) | 37.3 (37.3–37.4) | NS |
| Race/Ethnicity | <0.001 | |||
| Non-Hispanic White | 432,990 (75.9%) | 1,724 (70.3%) | 431,266 (75.9%) | |
| Non-Hispanic Black | 60,082 (10.5%) | 409 (16.7%) | 59,673 (10.5%) | |
| Hispanic | 30,292 (5.3%) | 137 (5.6%) | 30,155 (5.3%) | |
| Other | 22,773 (4%) | 80 (3.3%) | 22,693 (4%) | |
| Distance Traveled, miles - Median (IQR) | 8.9 (4.3 – 18.5) | 9.0 (4.2 – 19.1) | 8.9 (4.3 – 18.5) | 0.08 |
| Charlson/Deyo Comorbidity Score | <0.001 | |||
| 0 | 477,013 (83.6%) | 1,976 (80.6%) | 475,037 (83.6%) | |
| 1 | 76,852 (13.5%) | 372 (15.2%) | 76,480 (13.5%) | |
| ≥2 | 16,643 (2.9%) | 103 (4.2%) | 16,540 (2.9%) | |
| Income Level | <0.001 | |||
| <$30,000 | 59,140 (10.4%) | 301 (12.3%) | 58,839 (10.4%) | |
| $30,000–$34,999 | 86,654 (15.2%) | 409 (16.7%) | 86,245 (15.2%) | |
| $35,000–$45,999 | 148,048 (26%) | 647 (26.4%) | 14,7401 (25.9%) | |
| ≥$46,000 | 258,218 (45.3%) | 1,017 (41.5%) | 257,201 (45.3%) | |
| Insurance Status | <0.001 | |||
| Private | 301,066 (52.8%) | 1,149 (46.9%) | 299,917 (52.8%) | |
| Medicaid | 36,789 (6.4%) | 179 (7.3%) | 36,610 (6.4%) | |
| Medicare | 206,811 (36.3%) | 999 (40.8%) | 205,812 (36.2%) | |
| Other Government | 5,822 (1%) | 17 (0.7%) | 5,805 (1%) | |
| Not Insured | 11,486 (2%) | 49 (2%) | 11,437 (2%) | |
| Education Level | 0.004 | |||
| ≤71% High School Graduation Rate | 77,611 (13.6%) | 382 (15.6%) | 77,229 (13.6%) | |
| 71.1%–80% High School Graduation Rate | 116,014 (20.3%) | 518 (21.1%) | 115,496 (20.3%) | |
| 80.1%–86% High School Graduation Rate | 127,577 (22.4%) | 555 (22.6%) | 127,022 (22.4%) | |
| >86% High School Graduation Rate | 230,778 (40.5%) | 919 (37.5%) | 229,859 (40.5%) | |
| County Type | 0.51 | |||
| Metro | 472,612 (82.8%) | 2,022 (82.5%) | 470,590 (82.8%) | |
| Urban | 73,832 (12.9%) | 330 (13.5%) | 73,502 (12.9%) | |
| Rural | 9,560 (1.7%) | 47 (1.9%) | 9,513 (1.7%) | |
| Facility Type | <0.001 | |||
| Academic | 175,865 (30.8%) | 870 (35.5%) | 174,995 (30.8%) | |
| Integrated Network | 61,531 (10.8%) | 272 (11.1%) | 61,259 (10.8%) | |
| Comprehensive | 273,616 (48%) | 1,057 (43.1%) | 272,559 (48%) | |
| Community | 59,496 (10.4%) | 252 (10.3%) | 59,244 (10.4%) | |
| Facility Location | <0.001 | |||
| Midwest | 144,665 (25.4%) | 687 (28%) | 143,978 (25.3%) | |
| Northeast | 119,939 (21%) | 509 (20.8%) | 119,430 (21%) | |
| South | 205,418 (36%) | 899 (36.7%) | 204,519 (36%) | |
| West | 100,486 (17.6%) | 356 (14.5%) | 100,130 (17.6%) | |
| Receptor Group | <0.001 | |||
| TNBC | 65,852 (11.5%) | 1,724 (70.3%) | 64,128 (11.3%) | |
| HER2+ | 73,091 (12.8%) | 118 (4.8%) | 72,973 (12.8%) | |
| Luminal | 392,111 (68.7%) | 469 (19.1%) | 391,642 (68.9%) | |
| Clinical T Stage | <0.001 | |||
| 0 | 1,095 (0.2%) | 4 (0.2%) | 1,091 (0.2%) | |
| 1 | 334,321 (58.6%) | 697 (28.4%) | 333,624 (58.7%) | |
| 2 | 138,095 (24.2%) | 1,108 (45.2%) | 136,987 (24.1%) | |
| 3 | 23,910 (4.2%) | 284 (11.6%) | 23,626 (4.2%) | |
| 4 | 10,462 (1.8%) | 133 (5.4%) | 10,329 (1.8%) | |
| X | 35,987 (6.3%) | 146 (6%) | 35,841 (6.3%) | |
| Clinical N Stage | 0.42 | |||
| 0 | 444,088 (77.8%) | 1,923 (78.5%) | 442,165 (77.8%) | |
| 1 | 65,172 (11.4%) | 265 (10.8%) | 64,907 (11.4%) | |
| 2 | 11,293 (2%) | 58 (2.4%) | 11,235 (2%) | |
| 3 | 5,419 (0.9%) | 19 (0.8%) | 5,400 (1%) | |
| X | 29,870 (5.2%) | 122 (5%) | 29,748 (5.2%) | |
| Pathologic T Stage | <0.001 | |||
| 0 | 9,822 (1.7%) | 36 (1.5%) | 9,786 (1.7%) | |
| 1 | 366,396 (64.2%) | 754 (30.8%) | 365,642 (64.4%) | |
| 2 | 148,609 (26%) | 1,165 (47.5%) | 147,444 (26%) | |
| 3 | 22,461 (3.9%) | 333 (13.6%) | 22,128 (3.9%) | |
| 4 | 6,275 (1.1%) | 102 (4.2%) | 6,173 (1.1%) | |
| X | 4,881 (0.9%) | 21 (0.9%) | 4,860 (0.9%) | |
| Pathologic N Stage | <0.001 | |||
| 0 | 396,801 (69.6%) | 1,947 (79.4%) | 394,854 (69.5%) | |
| 1 | 115,550 (20.3%) | 337 (13.7%) | 115,213 (20.3%) | |
| 2 | 30,681 (5.4%) | 79 (3.2%) | 30,602 (5.4%) | |
| 3 | 14,796 (2.6%) | 29 (1.2%) | 14,767 (2.6%) | |
| X | 3,412 (0.6%) | 20 (0.8%) | 3,392 (0.6%) | |
| Tumor Size (cm) – Median (IQR) | 1.6 (1 – 2.5) | 3 (2 – 4.5) | 1.6 (1 – 2.5) | <0.001 |
| Grade | <0.001 | |||
| 1 | 125,026 (21.9%) | 51 (2.1%) | 124,975 (22%) | |
| 2 | 237,486 (41.6%) | 286 (11.7%) | 237,200 (41.8%) | |
| 3 | 170,576 (29.9%) | 1,768 (72.1%) | 168,808 (29.7%) | |
| Breast Surgery | <0.001 | |||
| Lumpectomy | 314,237 (55.1%) | 1,005 (41%) | 313,232 (55.1%) | |
| Mastectomy | 256,271 (44.9%) | 1,446 (59%) | 254,825 (44.9%) | |
| Diagnosis Timing | <0.001 | |||
| At Surgery | 50,029 (8.8%) | 307 (12.5%) | 49,722 (8.8%) | |
| Prior to Surgery | 513,799 (90.1%) | 2,121 (86.5%) | 511,678 (90.1%) | |
| Axillary Surgery | 0.001 | |||
| ALND | 183,517 (32.2%) | 863 (35.2%) | 182,654 (32.2%) | |
| SLNB | 386,991 (67.8%) | 1,588 (64.8%) | 385,403 (67.8%) | |
| Axillary Surgery + LN Status | <0.001 | |||
| ALND + No Positive LNs | 60,604 (10.6%) | 490 (20%) | 60,114 (10.6%) | |
| SLNB + No Positive LNs | 340,011 (59.6%) | 1,491 (60.8%) | 338,520 (59.6%) | |
| ALND + Positive LNs | 122,674 (21.5%) | 371 (15.1%) | 122,303 (21.5%) | |
| SLNB + Positive LNs | 46,668 (8.2%) | 96 (3.9%) | 46,572 (8.2%) | |
| Treatment with Radiation | <0.001 | |||
| Yes | 347,004 (60.8%) | 1,290 (52.6%) | 345,714 (60.9%) | |
| No | 218,911 (38.4%) | 1,135 (46.3%) | 217,776 (38.3%) | |
| Treatment with Radiation after Lumpectomya | 273,093 (86.9%) | 852 (84.8%) | 272,241 (86.9%) | 0.07 |
| Treatment with Chemotherapy | <0.001 | |||
| Yes | 246,547 (43.2%) | 1,816 (74.1%) | 244,731 (43.1%) | |
| No | 311,373 (54.6%) | 611 (24.9%) | 310,762 (54.7%) | |
| Chemotherapy Type | <0.001 | |||
| Adjuvant Only | 184,172 (32.3%) | 1,340 (54.7%) | 182,832 (32.2%) | |
| Neoadjuvant +/− Adjuvant | 62,115 (10.9%) | 476 (19.4%) | 61,639 (10.9%) | |
| No Chemotherapy | 311,373 (54.6%) | 611 (24.9%) | 310,762 (54.7%) | |
| Treatment with Endocrine Therapy | ||||
| Yes – Out of All Patients | 389,214 (68.2%) | 372 (15.2%) | 388,842 (68.5%) | <0.001 |
| No – Out of All Patients | 164,799 (28.9%) | 2,000 (81.6%) | 162,799 (28.7%) | |
| Yes – Out of HR+ Patients* | 383,744 (81.6%) | 326 (61.3%) | 383,418 (81.7%) | <0.001 |
| No – Out of HR+ Patients* | 73,237 (15.6%) | 188 (35.3%) | 73,049 (15.6%) | |
| # LNs Examined - Median (IQR) | 3 (2 – 8) | 4 (2 – 9) | 3 (2 – 8) | 0.01 |
| # Positive LNs - Median (IQR) | 0 (0 – 1) | 0 (0 – 0) | 0 (0 – 1) | <0.001 |
| LN Status | <0.001 | |||
| Any Positive LNs | 169,342 (29.7%) | 467 (19.1%) | 168,875 (29.7%) | |
| No Positive LNs | 400,615 (70.2%) | 1,981 (80.8%) | 398,634 (70.2%) |
a
Out of all patients who underwent lumpectomy.
*
Out of all patients who were ER+ and/or PR+.
ALND, axillary lymph node dissection; CI, confidence interval; IQR, interquartile range; LN, lymph node; SLNB, sentinel lymph node biopsy
All possible values are included for each covariate; some columns may not add to 100% due to the incomplete data.